Navigation Links
Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs

ing of our drug candidates. These statements involve significant risks and uncertainties, including those discussed in our annual report filed on form 10-K for the year ended June 30, 2006, our quarterly reports filed on Form 10-Q and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities, our ability to out-license our proprietary candidates on favorable terms, risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates, the ability of our collaborators and of Array to meet objectives tied to milestones and royalties, and our ability to attract and retain experienced scientists and management. We are providing this information as of June 20, 2007. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.

Contact

Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
ir@arraybiopharma.com


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
Post Your Comments:
(Date:8/31/2015)... , Aug. 31, 2015 The Wolf ... statewide since Pennsylvania State Police ... drug kits, naloxone. Heroin and opioid overdose ... Pennsylvania , killing more individuals than those ... 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... Calif. , Aug. 31, 2015  Regulatory ... and government, where regulations are often strict and ... is driving a demand for professionals who have ... these regulations across a product lifecycle and demonstrate ... The University of California, Irvine Extension , ...
(Date:8/31/2015)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ), the nation,s largest ... Chairman & CEO, and Sean Whelan , CFO, will ... Hagerman and Mr. Whelan are scheduled to participate in the ... on Wednesday, September 9, 2015 at 1:45 PM ET. ... to participate in the Robert W. Baird 2015 Healthcare Conference ...
Breaking Medicine Technology:Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Diplomat to Participate in Upcoming Investor Conferences 2
... PALO ALTO, Calif., Sept. 11 Jazz,Pharmaceuticals, Inc. (Nasdaq: ... completed participation in the first Phase III pivotal clinical ... The JZP-6 Phase III clinical trial program includes ... 550,fibromyalgia patients at 65 centers in the U.S. The ...
... 10 As a surgeon and clinical,instructor, Dr. ... the,growing number of patients contracting ... and dying ... aware that infections are quickly,spreading beyond the healthcare ... A 2004 study supervised by Dr. Deal tracked ...
Cached Medicine Technology:Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia 2Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia 3Doctor Declares War on Hospital Infections, Patents MRSA-Killing Machine 2
(Date:8/31/2015)... , ... August 31, 2015 , ... In an ... Press, the expert guest author addressed the topic of treating back pain caused by ... while steroids were shown to slightly improve physical function in patients suffering from a ...
(Date:8/31/2015)... ... August 31, 2015 , ... Wound Care Advantage, a leader ... Introduction to Hyperbaric Medicine Course. The next UHMS approved 40-hour Introduction to Hyperbaric ... in Long Beach, CA. The meeting is open for registration from physicians, clinicians ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... management program that is unique to the Lake Orion area. This program is ... County. , WEmovestrong’s weight management program will incorporate group fitness and nutritional ...
(Date:8/31/2015)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... August ... ... Movestrong, has launched pre and postnatal fitness classes. , Starting September ... The classes are called "The Mom Bod" and "Healthy Body, Healthy Baby." , ...
(Date:8/31/2015)... Los Angeles, CA (PRWEB) , ... August 31, 2015 , ... ... to start from and those who are interested in learning more about the procedure ... Dr. Parsa Mohebi. , Internationally recognized hair transplant surgeon Parsa Mohebi will be ...
Breaking Medicine News(10 mins):Health News:Article on Steroid Use for Back Pain Highlights the Effectiveness of Surgery in Treating Disk Pain, says Dr. Seyed M. Rezaian 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2
... add anti-smoking public service announcements to all DVD releases ... Attorney General // Joseph Curran initiated the petition after ... smoking in movies are more likely to begin smoking.' ... sign their names on a letter he sent to ...
... claim of having produced and purified stem cells from human ... in the British medical fraternity. ,The Guardian reported Friday ... impose tighter curbs on clinics in India that make extravagant ... doctor whose claims have evoked some concern here is Geeta ...
... licensed therapists do is no laughing matter. These ... 49 laughing therapists recently passed their // examinations and ... their immune system, and in general to help prevent ... the organizing Nihon Medical School., ,A doctor herself, ...
... high-risk medication by the FDA, doctors have been found to ... patients found to receive // such drugs was nearly ... and Harvard Pilgrim Health Care. ,The response of the ... variable, with noncompliance rates soaring from 0.3 % to 49.6%. ...
... a King County Superior Court jury in Seattle, Dr. Charles ... two counts // of rape and two counts of indecent ... treatment. ,Momah could face 16 years in prison if ... ,Momah pleaded not guilty last year to two counts ...
... performed a rare mother-to-son nerve transplant on Thursday, hoping to ... surgery on Nick Anderson of Atco, N.J., went as planned, ... in a few months, said Eric Vohr, a spokesman for ... success in three months, in about a year they should ...
Cached Medicine News:Health News:British Scientists Doubt Delhi Doctor’s Stem Cell Claim 2Health News:Are You Ill? Have A Hard Laugh! 2Health News:Doctors Do Not Excise Sufficient Caution While Prescribing High-Risk Drugs 2Health News:Doctors Finish Mother-To-Son Nerve Surgery 2
... Erythropoietin (EPO) is the primary known ... The predicted molecular weight of human EPO ... circulating form of EPO has an estimated ... itself appears to have a unique structure, ...
... the parafollicular C-cells of the thyroid gland ... major action of calcitonin is to lower ... resulting in decreased mobilization of calcium from ... in conditions associated with high levels of ...
... (hCG) is a two chain (alpha- and ... tissue of the placenta and is normally ... Produced by the trophoblastic epithelium of the ... luteum in the early stages of pregnancy. ...
... Compensating for movement is ... in wheelchairs. Thats why ... exclusive technology to do ... with state-of-the-art technology, these ...
Medicine Products: